An interventional study of Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect and occupational therapy conventional treatment in Stroke and Neglect, Hemispatial, sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia. Enrolling by invitation at 1 site in Argentina. Open to participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Stroke with a site in Argentina — 9 open to participants now, 12 under way, 3 of them phase 3. Stroke · Argentina.
Among the 50 studies in Stroke with a site in Argentina, this one is the 36th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 with no phase, reaches primary completion later than 0 of the 11 other live ones, and was the 48th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →9 of the 50 studies in Stroke with a site in Argentina are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Argentina, Australia, Austria and 35 more countries
Ages 50+
Regeneron Pharmaceuticals · Sites in Argentina, United States, Brazil and 1 more country
Ages 18+
Ramos Mejía Hospital · Sites in Argentina
Ages 16+
McMaster University · Sites in Argentina, Canada
Ages 18+
Philips Clinical & Medical Affairs Global · Sites in Argentina, United States, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 88 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 5,390 across the 37 interventional studies, 535 across the 13 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 50 have an industry lead sponsor. The 10 most frequent:
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia has 3 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
7 of the studies in Stroke with a site in Argentina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07475611Fundación para la Lucha contra las Enfermedades Neurológicas de la InfanciaEffectiveness of an Interactive Screen in the Rehabilitation of Neglect in Adults With Subacute Stroke: A Randomized Controlled Trial in Argentina. | 2026-12-01 |
| NCT04562194VesalioNeVa ONE Registry Study | 2026-12-31 |
| NCT06964724VesalioNeVa Retrospective Comparative SR Study | 2027-02-01 |
| NCT07175428Regeneron PharmaceuticalsSafety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | 2027-02-09 |
| NCT04701684Philips Clinical & Medical Affairs GlobalWE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment) | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 50 studies in Stroke with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hemispatial neglect is one of the most frequent and disabling sequelae after a stroke, particularly following right-hemisphere lesions. Its prevalence ranges from 25% to 80% and is associated with poorer functional outcomes, increased risk of falls, prolonged hospital stays, and lower rates of discharge to home. In response to these challenges, rehabilitation technologies have emerged as promising tools, especially during the subacute phase of stroke, a critical period for neuroplasticity. The MYRO® device-an adjustable interactive screen that enables intensive, task-oriented training-has shown benefits in promoting visual scanning, midline crossing, and sensorimotor integration through personalized exercises with constant feedback.
This study aims to evaluate the effectiveness of MYRO® combined with conventional occupational therapy in patients with left hemispatial neglect secondary to subacute stroke. A randomized clinical trial will be conducted with 30 participants assigned to two groups: conventional occupational therapy (OT-C) and occupational therapy plus rehabilitation technology using MYRO® (OT-M). Both groups will receive interventions for four weeks, with assessments at baseline, at the end of the protocol, and at a six-week follow-up. Outcome measures will include the NIHSS, FIM, Catherine Bergego Scale, Cancelation Bells Test, and Line Bisection Test.
It is expected that the use of MYRO® will enhance visuospatial attention toward the left hemifield and accelerate functional recovery compared with conventional treatment alone. The results could provide relevant evidence supporting the integration of interactive technology into neurofunctional rehabilitation within the Argentine context.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Conventional occupational therapy intervention for the treatment of neglect
Other: occupational therapy conventional treatment
Use of an interactive screen for neglect rehabilitation
Device: Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect
Use of the Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect
Bottom - up, restorative occupational therapy approach to unilateral neglect
Catherine Bergego Scale for Neglect
The Catherine Bergego Scale (CBS) is a functional assessment composed of 10 items, each scored on a 0-3 scale, resulting in a total score ranging from 0 to 30. A score of 0 indicates the absence of neglect, whereas a score of 30 reflects severe unilateral neglect. Higher total scores represent worse performance and greater severity of neglect, while lower scores indicate better functional outcomes. Severity levels are commonly categorized as follows: 1-10 points indicate mild behavioral neglect, 10-20 indicate moderate neglect, and 21-30 represent severe behavioral neglect.
Time frame: from the start of treatment until 4 weeks
Plan to share: Undecided — Only IPDs used for the publication of the results will be included.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 14 months is below that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia